Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure

Recruiting now

Conditions studied: Heart Failure NYHA Class III, Heart Failure

In brief

This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.

Key facts

Study ID

NCT06783335

Run by

Endotronix, Inc.

People needed

2150

Starts

2025-02-07

Expected to finish

2030-12-31

Last updated by the study team

2025-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• No implanted pulmonary artery sensor or monitoring at any time (Standard of Care Control Cohort only)
• Record of temporary mechanical circulatory support during baseline period
• Diagnosis of cardiogenic shock during baseline period
• Receiving palliative care/hospice during baseline period
• Record of end-stage renal disease during baseline period
• Unable to take dual antiplatelet therapy or anticoagulants for one month post implant (Cordella Cohort only)

Where it is running

• Endotronix — Naperville, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.